Proxygen Announces Formation of Scientific Advisory Board
November 15, 2023 07:00 ET
|
Proxygen
SAB Comprised of Pioneers in the Field of Protein Degradation, Including Unique Expertise in Roles of Ubiquitin Biology and Translational Medicine Track Records of Founding Biopharma Companies and...
Fierce Biotech Names Proxygen a “Fierce 15” Biotech Company of 2023
August 28, 2023 06:00 ET
|
Proxygen
VIENNA, Austria, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Proxygen, a leader in the discovery and development of molecular glue degraders, today announced that Fierce Biotech has named it as one of 2023’s...
Proxygen gibt Kooperation und Lizenzvereinbarung mit MSD für die Entdeckung und Entwicklung neuartiger Molecular Glue Degraders bekannt
April 05, 2023 10:55 ET
|
Proxygen
WIEN, Österreich, April 05, 2023 (GLOBE NEWSWIRE) -- Proxygen, ein führendes Unternehmen im Bereich der Entdeckung und Entwicklung von Molecular Glue Degraders, gab heute bekannt, dass es eine...
Proxygen annonce un accord de collaboration et de licence avec MSD portant sur la découverte et le développement de nouveaux dégradeurs de colles moléculaires
April 05, 2023 10:55 ET
|
Proxygen
VIENNE, Autriche, 05 avr. 2023 (GLOBE NEWSWIRE) -- Proxygen, un chef de file dans la découverte et le développement de dégradeurs de colles moléculaires, a annoncé aujourd'hui un accord de...
Proxygen Announces Collaboration and License Agreement with MSD for the Discovery and Development of Novel Molecular Glue Degraders
April 05, 2023 07:00 ET
|
Proxygen
VIENNA, Austria, April 05, 2023 (GLOBE NEWSWIRE) -- Proxygen, a leader in the discovery and development of molecular glue degraders, announced today a multi-year research collaboration and license...
Proxygen Announces Formation of Board of Directors
March 15, 2023 07:00 ET
|
Proxygen
VIENNA, Austria, March 15, 2023 (GLOBE NEWSWIRE) -- Proxygen, a leader in the discovery and development of molecular glue degraders, today announced the formation of the company’s board of...